Google's Dr. Karen DeSalvo and Merck & Co. CEO Kenneth Frazier talk about why the recent temporary pauses on vaccine trials are very important and are a positive thing in the race for a vaccine.
Watch the full talk: kzread.info/dash/bejne/h3WlvK-gcterc7Q.html
Google Zeitgeist is a collection of talks by people who are changing the world. Hear entrepreneurs, CEOs, storytellers, scientists, and dreamers share their visions of how we can shape tomorrow.
Dr. Karen DeSalvo is the Chief Health Officer of Google Health. She is a physician leader working at the intersection of medicine, public health, and information technology whose career has focused on improving health and eliminating disparities. She leads a team of health professionals at Google who provide clinical guidance for the development of research, products and services. Prior to joining Google, Dr. DeSalvo was National Coordinator for Health Information Technology and acted as the Assistant Secretary for Health in the Obama Administration. During her time at the U.S. Department of Health and Human Services, Dr. DeSalvo focused on creating a more consumer-oriented, transparent and value-based health system. Dr. DeSalvo served as the New Orleans Health Commissioner following Hurricane Katrina. Prior to that she was Vice Dean for Community Affairs and Health Policy at the Tulane School of Medicine where she was a practicing physician, educator, researcher and leader. She serves on the Council of the National Academy of Medicine.
Kenneth C. Frazier has served as the Chairman of the Board and Chief Executive Officer of Merck & Co., Inc. since 2011. Under Ken's leadership, Merck is delivering innovative lifesaving medicines and vaccines as well as long-term and sustainable value to its multiple stakeholders. Ken has substantially increased Merck's investment in research, including early research, while refocusing the organization on the launch and growth of key products that provide benefit to society. He has also led the formation of philanthropic and other initiatives that build on Merck's 125-year plus legacy. Ken joined the company in 1992 and has held positions of increasing responsibility including General Counsel and President. Prior to joining Merck, Ken was a partner with the Philadelphia law firm of Drinker Biddle & Reath. Ken's contributions, especially in the legal, business and humanitarian fields, have been widely recognized. He sits on the boards of PhRMA, Weill Cornell Medicine, Exxon Mobil Corporation, and Cornerstone Christian Academy in Philadelphia, PA. He also is a member of the American Academy of Arts and Sciences, the American Philosophical Society, The Business Council, the Council of the American Law Institute, and the American Bar Association. Additionally, Ken is co-chair of the Legal Services Corporation's Leaders Council.